P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 851-852
10.1097/01.hs9.0000846712.74284.0f